MX2019008413A - Celulas pluripotentes inmunodiseñadas. - Google Patents
Celulas pluripotentes inmunodiseñadas.Info
- Publication number
- MX2019008413A MX2019008413A MX2019008413A MX2019008413A MX2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A
- Authority
- MX
- Mexico
- Prior art keywords
- pluripotent cells
- avoid
- provides
- immunoengineered
- rejection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/005—Vectors comprising a special translation-regulating system cell cycle specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01021—Thymidine kinase (2.7.1.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04001—Cytosine deaminase (3.5.4.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La invención proporciona células pluripotentes que se usan terapéuticamente para regenerar tejidos que evitan el rechazo de los sujetos que las reciben. En particular, la invención proporciona células pluripotentes hipoinmunogénicas que evitan el rechazo inmune del huésped. Las células carecen de antígenos inmunes importantes que desencadenan respuestas inmunes y están diseñadas para evitar la endocitosis fagocítica. La invención proporciona además células pluripotentes "disponibles en el mercado" universalmente aceptables y derivados de las mismas para generar o regenerar tejidos y órganos específicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762445969P | 2017-01-13 | 2017-01-13 | |
PCT/US2018/013688 WO2018132783A1 (en) | 2017-01-13 | 2018-01-14 | Immunoengineered pluripotent cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019008413A true MX2019008413A (es) | 2019-09-13 |
Family
ID=61148505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019008413A MX2019008413A (es) | 2017-01-13 | 2018-01-14 | Celulas pluripotentes inmunodiseñadas. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20190376045A1 (es) |
EP (1) | EP3568464A1 (es) |
JP (2) | JP2020505025A (es) |
KR (1) | KR20190103373A (es) |
CN (1) | CN110177869A (es) |
AU (1) | AU2018207649A1 (es) |
BR (1) | BR112019014257A2 (es) |
CA (1) | CA3049766A1 (es) |
EA (1) | EA201991692A1 (es) |
IL (1) | IL267616A (es) |
MX (1) | MX2019008413A (es) |
NZ (1) | NZ754898A (es) |
WO (1) | WO2018132783A1 (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015360502A1 (en) | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
CN107921148A (zh) | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
BR112019018124A2 (pt) | 2017-03-22 | 2020-04-07 | Intellia Therapeutics Inc | composições e métodos para imunooncologia |
US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
WO2020018620A1 (en) * | 2018-07-17 | 2020-01-23 | The Regents Of The University Of California | Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells |
US20200080107A1 (en) | 2018-09-07 | 2020-03-12 | Crispr Therapeutics Ag | Universal donor cells |
WO2020067993A1 (en) * | 2018-09-26 | 2020-04-02 | National University Of Singapore | Engineered human mesenchymal stromal cells with low immunogenicity, methods and kits of generating the same |
UY38427A (es) * | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
CN111424016A (zh) * | 2019-01-09 | 2020-07-17 | 复旦大学 | 降低细胞免疫原性的诱导型多能干细胞系及建立方法 |
KR20210128440A (ko) * | 2019-02-15 | 2021-10-26 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 범용 공여자 줄기 세포 및 관련 방법 |
JP2022532174A (ja) * | 2019-05-10 | 2022-07-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 修飾多能性細胞 |
US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
JP2022540012A (ja) | 2019-06-26 | 2022-09-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | SIRPαがサイレンシングされたナチュラルキラー(NK)細胞 |
TW202115245A (zh) * | 2019-06-27 | 2021-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | 安全免疫隱形細胞 |
EP4022037A1 (en) | 2019-07-10 | 2022-07-06 | Helmuth Heinrich Kunz | Methods for deriving autologous and hypoimmunogenic hair follicle containing sheets in vitro |
JP2022543112A (ja) | 2019-08-01 | 2022-10-07 | サナ バイオテクノロジー,インコーポレイテッド | Dux4発現細胞およびそれらの使用 |
JP2022546317A (ja) | 2019-08-23 | 2022-11-04 | サナ バイオテクノロジー,インコーポレイテッド | Cd24発現細胞およびそれらの用途 |
WO2021044379A1 (en) | 2019-09-05 | 2021-03-11 | Crispr Therapeutics Ag | Universal donor cells |
JP2022547053A (ja) | 2019-09-05 | 2022-11-10 | クリスパー セラピューティクス アクチェンゲゼルシャフト | ユニバーサルドナー細胞 |
CN114729368A (zh) * | 2019-09-09 | 2022-07-08 | 斯克里贝治疗公司 | 用于免疫疗法的组合物和方法 |
WO2021055985A1 (en) * | 2019-09-22 | 2021-03-25 | Cellerant Therapeutics, Inc. | Ipsc-derived, hypoimmunogenic, myeloid progenitor cells |
AU2020365937A1 (en) * | 2019-10-15 | 2022-04-28 | The Regents Of The University Of California | Transplanted cell protection via Fc sequestration |
CN116234906A (zh) | 2020-01-13 | 2023-06-06 | 萨那生物技术股份有限公司 | 血型抗原的修饰 |
KR20220142433A (ko) | 2020-01-17 | 2022-10-21 | 사나 바이오테크놀로지, 인크. | 유전자 발현 조절용 안전 스위치 |
AU2021241643A1 (en) | 2020-03-25 | 2022-11-24 | Sana Biotechnology, Inc. | Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions |
CN115916252A (zh) * | 2020-04-21 | 2023-04-04 | 因提玛生物科学公司 | 细胞疫苗平台和使用方法 |
US20230338533A1 (en) * | 2020-05-15 | 2023-10-26 | Rxcell Inc. | Hypoimmunogenic Cells and Uses Thereof in Immune Responses |
AU2021325941A1 (en) | 2020-08-13 | 2023-03-09 | Sana Biotechnology, Inc. | Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions |
CN112342196A (zh) * | 2020-08-18 | 2021-02-09 | 未来智人再生医学研究院(广州)有限公司 | 一种免疫兼容可逆的通用型多能干细胞及其应用 |
CA3196346A1 (en) * | 2020-10-20 | 2022-04-28 | Herman Waldmann | Methods and compositions for cellular therapy |
CN114525255A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-11的多能干细胞衍生物及其应用 |
CN114457021A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd47抗体的多能干细胞及其衍生物与应用 |
US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
CN114107211A (zh) * | 2020-12-04 | 2022-03-01 | 未来智人再生医学研究院(广州)有限公司 | 一种多能干细胞及其衍生物 |
EP4271795A1 (en) | 2020-12-31 | 2023-11-08 | CRISPR Therapeutics AG | Universal donor cells |
WO2022146891A2 (en) | 2020-12-31 | 2022-07-07 | Sana Biotechnology, Inc. | Methods and compositions for modulating car-t activity |
EP4301380A1 (en) | 2021-03-03 | 2024-01-10 | Sana Biotechnology, Inc. | Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions |
JPWO2022191216A1 (es) * | 2021-03-09 | 2022-09-15 | ||
JP2024515037A (ja) * | 2021-03-30 | 2024-04-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改変Fc受容体による移植細胞保護 |
KR20240011184A (ko) * | 2021-05-24 | 2024-01-25 | 상가모 테라퓨틱스, 인코포레이티드 | Ciita 표적화 아연 핑거 뉴클레아제 |
EP4347797A1 (en) | 2021-05-27 | 2024-04-10 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
CA3225283A1 (en) | 2021-07-14 | 2023-01-19 | Sonja SCHREPFER | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
CA3227613A1 (en) | 2021-08-11 | 2023-02-16 | William Dowdle | Inducible systems for altering gene expression in hypoimmunogenic cells |
AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
CA3227108A1 (en) | 2021-08-11 | 2023-02-16 | Xiaomeng HU | Genetically modified primary cells for allogeneic cell therapy |
WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
CN113801881B (zh) * | 2021-08-27 | 2024-02-20 | 浙江大学 | 超级增强子基因序列在促进人b2m基因表达中的用途 |
WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
CN114958768B (zh) * | 2022-06-02 | 2023-03-24 | 健颐生物科技发展(山东)有限公司 | Fgf10旁分泌通用型人成纤维细胞制剂的制备方法 |
CN117343962A (zh) * | 2022-06-29 | 2024-01-05 | 中国科学院上海营养与健康研究所 | 免疫兼容型人多能干细胞、其制备方法及应用 |
WO2024003349A1 (en) | 2022-07-01 | 2024-01-04 | Novo Nordisk A/S | Enhancing neuronal differentiation of ventral midbrain neural progenitor cells |
CN117384851A (zh) * | 2022-07-11 | 2024-01-12 | 士泽生物医药(苏州)有限公司 | 一种表达faslg的通用型细胞及其制备方法 |
CN117431217A (zh) * | 2022-07-12 | 2024-01-23 | 上海驯鹿生物技术有限公司 | 表达靶向cd5的嵌合抗原受体(car)的细胞及其应用 |
GB202211117D0 (en) * | 2022-07-29 | 2022-09-14 | Replay Holdings Llc | Compositions and methods for non-immunogenecity |
GB202212144D0 (en) * | 2022-08-19 | 2022-10-05 | Resolution Therapeutics Ltd | Cells for therapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
CN102459575A (zh) * | 2009-06-05 | 2012-05-16 | 细胞动力国际有限公司 | 重编程t细胞和造血细胞的方法 |
WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
EP4253409A3 (en) * | 2012-04-17 | 2023-12-06 | University of Washington through its Center for Commercialization | Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof |
AU2015249371B2 (en) * | 2014-04-24 | 2020-04-30 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
US11186824B2 (en) * | 2015-03-11 | 2021-11-30 | Cellectis | Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients |
CN107921148A (zh) * | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
WO2017079673A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
-
2018
- 2018-01-14 AU AU2018207649A patent/AU2018207649A1/en active Pending
- 2018-01-14 CN CN201880006714.XA patent/CN110177869A/zh active Pending
- 2018-01-14 EP EP18702859.2A patent/EP3568464A1/en active Pending
- 2018-01-14 US US16/476,794 patent/US20190376045A1/en active Pending
- 2018-01-14 CA CA3049766A patent/CA3049766A1/en active Pending
- 2018-01-14 EA EA201991692A patent/EA201991692A1/ru unknown
- 2018-01-14 BR BR112019014257A patent/BR112019014257A2/pt unknown
- 2018-01-14 MX MX2019008413A patent/MX2019008413A/es unknown
- 2018-01-14 JP JP2019538202A patent/JP2020505025A/ja active Pending
- 2018-01-14 NZ NZ754898A patent/NZ754898A/en unknown
- 2018-01-14 KR KR1020197023696A patent/KR20190103373A/ko not_active IP Right Cessation
- 2018-01-14 WO PCT/US2018/013688 patent/WO2018132783A1/en unknown
-
2019
- 2019-06-24 IL IL267616A patent/IL267616A/en unknown
-
2022
- 2022-12-26 JP JP2022208126A patent/JP2023052079A/ja active Pending
-
2023
- 2023-03-29 US US18/127,936 patent/US20230348862A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018207649A1 (en) | 2019-07-11 |
KR20190103373A (ko) | 2019-09-04 |
CN110177869A (zh) | 2019-08-27 |
IL267616A (en) | 2019-08-29 |
BR112019014257A2 (pt) | 2020-04-28 |
JP2020505025A (ja) | 2020-02-20 |
US20230348862A1 (en) | 2023-11-02 |
CA3049766A1 (en) | 2018-07-19 |
EA201991692A1 (ru) | 2019-12-30 |
EP3568464A1 (en) | 2019-11-20 |
WO2018132783A1 (en) | 2018-07-19 |
NZ754898A (en) | 2023-11-24 |
US20190376045A1 (en) | 2019-12-12 |
JP2023052079A (ja) | 2023-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019008413A (es) | Celulas pluripotentes inmunodiseñadas. | |
MX2021000614A (es) | Células diferenciadas de células pluripotentes inmunodiseñadas. | |
PH12019500709A1 (en) | Anti-lag-3 antibodies and methods of use thereof | |
PH12017500803A1 (en) | Anti-pd-1 antibodies | |
PH12019500193A1 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
MX2022001222A (es) | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos. | |
MX2019005127A (es) | Poblaciones y productos de células madre mesenquimales y sus usos. | |
PH12017501342A1 (en) | Glycan therapeutics and related methods thereof | |
MX2019006598A (es) | Celulas asesinas naturales modificadas geneticamente y sus usos. | |
NZ737471A (en) | Hydrophilic linkers for conjugation | |
NZ730563A (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
MY191944A (en) | Binding proteins and methods of use thereof | |
JOP20190134A1 (ar) | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها | |
PH12019502036A1 (en) | Peptides and methods for the treatment of diabetes | |
WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
WO2019099578A8 (en) | Use of imidazopyrimidine for modulating human immune response | |
MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
PH12018502139A1 (en) | Phosphaplatin liquid formulations | |
PH12017501979A1 (en) | Pharmaceutical compound | |
MX2019014475A (es) | Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas. | |
EA202190296A1 (ru) | Клетки, дифференцированные из плюрипотентных клеток, полученных методами иммуноинженерии | |
MX2018003317A (es) | Celulas t modificadas que tienen propiedades anti-fuctacticas y sus usos. |